Immatics Nv Stock Investor Sentiment

IMTX Stock  USD 7.18  0.09  1.24%   
Slightly above 62% of Immatics' investor base is looking to short. The analysis of the overall investor sentiment regarding Immatics NV suggests that many traders are alarmed. Immatics' investing sentiment can be driven by a variety of factors including economic data, Immatics' earnings reports, geopolitical events, and overall market trends.
  

Immatics Sentiment by Major News Outlets

Investor sentiment, mood or attitude towards Immatics can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.
over a year ago at thelincolnianonline.com         
Q3 2023 EPS Estimates for Immatics Boosted by Leerink Partnrs
news
over a year ago at news.google.com         
Mainz Biomed Paves The Way For Early Colorectal Cancer Diagnosis And Even Prevention - Mainz Biomed ...
Google News at Macroaxis
over a year ago at finance.yahoo.com         
Protalix BioTherapeutics Appoints Eliot Richard Forster, Ph.D. as Chairman of its Board of Directors
Yahoo News
over a year ago at news.google.com         
Immatics surges on cancer drug deal with Moderna worth up to 1.8 ... - Investing.com
Google News at Macroaxis
over a year ago at cnbc.com         
Stocks making the biggest moves midday Tesla, Qualcomm, Meta, Moderna and more
cnbc News
over a year ago at bizjournals.com         
Moderna enters cancer collaboration with Immatics worth 1.8B
bizjournals News
over a year ago at marketwatch.com         
Immatics shares rise on Moderna cancer collaboration
marketwatch News
over a year ago at marketwatch.com         
Immatics shares rise on Moderna cancer collaboration
marketwatch News
over a year ago at finance.yahoo.com         
Those who invested in Immatics three years ago are up 27
Yahoo News
over a year ago at zacks.com         
How Much Upside is Left in Immatics Wall Street Analysts Think 45.78
zacks News
over a year ago at thelincolnianonline.com         
Immatics Trading 4.6 percent Higher
news
over a year ago at thelincolnianonline.com         
Immatics Shares Gap Down to 11.38
news
over a year ago at seekingalpha.com         
Immatics GAAP EPS of -0.32, revenue of 22.4M
seekingalpha News
over a year ago at simplywall.st         
Institutional owners may take dramatic actions as Immatics N.V.s recent 5.3 percent drop adds to one...
Simply Wall St News at Macroaxis
over a year ago at globenewswire.com         
Immatics verffentlicht Ergebnisse des zweiten Quartals 2023 sowie ein Update zur Geschftsentwicklung
Macroaxis News: globenewswire.com
Far too much social signal, news, headlines, and media speculation about Immatics that are available to investors today. That information is available publicly through Immatics media outlets and privately through word of mouth or via Immatics internal channels. However, regardless of the origin, that massive amount of Immatics data is challenging to quantify into actionable patterns, especially for investors that are not very sophisticated with ever-evolving tools and techniques used in the investment management field.
A primary focus of Immatics news analysis is to determine if its current price reflects all relevant headlines and social signals impacting the current market conditions. A news analyst typically looks at the history of Immatics relative headlines and hype rather than examining external drivers such as technical or fundamental data. It is believed that price action tends to repeat itself due to investors' collective, patterned thinking related to Immatics' headlines and news coverage data. This data is often completely overlooked or insufficiently analyzed for actionable insights to drive Immatics alpha.

Immatics Performance against Dow Jones

 Price Growth (%)  
       Timeline  
1
Immatics stock falls as it looks to raise 150M via public offering
10/10/2024
2
Immatics Announces Pricing of 150 Million Public Offering
10/11/2024
3
Immatics Sees Significant Decrease in Short Interest
10/16/2024
4
Immatics Short Interest Update
10/31/2024
5
Analysts Estimate Avidity Biosciences, Inc. to Report a Decline in Earnings What to Look Out for
11/06/2024
6
Immatics Announces Third Quarter 2024 Financial Results, Busines
11/18/2024
7
Bank of America Cuts Immatics Price Target to 15.00
11/19/2024
8
Immatics FY2024 EPS Forecast Increased by Leerink Partnrs
11/21/2024

Additional Tools for Immatics Stock Analysis

When running Immatics' price analysis, check to measure Immatics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Immatics is operating at the current time. Most of Immatics' value examination focuses on studying past and present price action to predict the probability of Immatics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Immatics' price. Additionally, you may evaluate how the addition of Immatics to your portfolios can decrease your overall portfolio volatility.